Inhibition of oxygen-centered free radical formation by the stable prostacyclin-mimetic iloprost (ZK 36 374) in acute myocardial ischemia. 1984

C Thiemermann, and E Steinhagen-Thiessen, and K Schrör

UI MeSH Term Description Entries
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D002317 Cardiovascular Agents Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. Cardioactive Agent,Cardioactive Drug,Cardiovascular Agent,Cardiovascular Drug,Cardioactive Agents,Cardioactive Drugs,Cardiovascular Drugs,Agent, Cardioactive,Agent, Cardiovascular,Drug, Cardioactive,Drug, Cardiovascular
D002415 Cats The domestic cat, Felis catus, of the carnivore family FELIDAE, comprising over 30 different breeds. The domestic cat is descended primarily from the wild cat of Africa and extreme southwestern Asia. Though probably present in towns in Palestine as long ago as 7000 years, actual domestication occurred in Egypt about 4000 years ago. (From Walker's Mammals of the World, 6th ed, p801) Felis catus,Felis domesticus,Domestic Cats,Felis domestica,Felis sylvestris catus,Cat,Cat, Domestic,Cats, Domestic,Domestic Cat
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005609 Free Radicals Highly reactive molecules with an unsatisfied electron valence pair. Free radicals are produced in both normal and pathological processes. Free radicals include reactive oxygen and nitrogen species (RONS). They are proven or suspected agents of tissue damage in a wide variety of circumstances including radiation, damage from environment chemicals, and aging. Natural and pharmacological prevention of free radical damage is being actively investigated. Free Radical
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013481 Superoxides Highly reactive compounds produced when oxygen is reduced by a single electron. In biological systems, they may be generated during the normal catalytic function of a number of enzymes and during the oxidation of hemoglobin to METHEMOGLOBIN. In living organisms, SUPEROXIDE DISMUTASE protects the cell from the deleterious effects of superoxides. Superoxide Radical,Superoxide,Superoxide Anion
D016285 Iloprost An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation. Ciloprost,Ventavis,ZK-36374,ZK 36374,ZK36374

Related Publications

C Thiemermann, and E Steinhagen-Thiessen, and K Schrör
January 1984, Biomedica biochimica acta,
C Thiemermann, and E Steinhagen-Thiessen, and K Schrör
November 1986, Journal of the American College of Cardiology,
C Thiemermann, and E Steinhagen-Thiessen, and K Schrör
January 1985, Acta haematologica,
C Thiemermann, and E Steinhagen-Thiessen, and K Schrör
August 1984, Prostaglandins, leukotrienes, and medicine,
C Thiemermann, and E Steinhagen-Thiessen, and K Schrör
October 1981, The Journal of pharmacology and experimental therapeutics,
C Thiemermann, and E Steinhagen-Thiessen, and K Schrör
January 1983, Advances in prostaglandin, thromboxane, and leukotriene research,
C Thiemermann, and E Steinhagen-Thiessen, and K Schrör
July 1985, Lancet (London, England),
C Thiemermann, and E Steinhagen-Thiessen, and K Schrör
January 1984, Biomedica biochimica acta,
C Thiemermann, and E Steinhagen-Thiessen, and K Schrör
January 1986, Prostaglandins, leukotrienes, and medicine,
C Thiemermann, and E Steinhagen-Thiessen, and K Schrör
February 1984, Prostaglandins, leukotrienes, and medicine,
Copied contents to your clipboard!